India allows Serum Institute to enrol 7-11 year olds in COVID-19 vaccine trial

India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its trial of U.S. drugmaker Novavax's COVID-19 vaccine, as the country prepares to protect children from the novel coronavirus. The South Asian nation has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.